Literature DB >> 8763887

Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy.

M Nordsmark1, R J Maxwell, P J Wood, I J Stratford, G E Adams, J Overgaard, M R Horsman.   

Abstract

Hydralazine can substantially decrease the blood flow, oxygen status and energy metabolism of transplanted tumours. In spontaneous tumours, two recent studies reported no effects of hydralazine on energy metabolism measured by 31P-magnetic resonance spectroscopy (31P-MRS), although another study saw changes in oxygen partial pressure (pO2) distributions measured with electrodes. We have now performed 31P-MRS and pO2 measurements in the same T138 spontaneous tumours, before and after intravenously (i.v.) injecting anaesthetised mice with 5 mg kg-1 hydralazine. Tumour pO2 was measured with an Eppendorf oxygen electrode and 31P-MRS spectra obtained with a 7-tesla SISCO magnet. Of 12 tumours all showed an increase in the percentage of pO2 values < or = 5 mmHg after hydralazine treatment and 10/12 showed a decrease in median pO2. The average (+/-1 s.e.) values for the percentage < or = 5 mmHg went from 45% (+/-9) to 79% (+/-5) and the median from 9 mmHg (+/-2) to 2 mmHg (+/-1). With the 31P-MRS 8/12 tumours showed an increase in the ratio of the peaks of inorganic phosphate to beta-nucleoside triphosphate with the average (+/-1 s.e.) values going from 1.1 (+/-0.2) to 2.4 (+/-0.9). Thus spontaneous tumours can respond to hydralazine and do so in a way consistent with that reported for transplanted tumours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763887      PMCID: PMC2149994     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  18 in total

1.  Accurate quantification of in vivo 31P NMR signals using the variable projection method and prior knowledge.

Authors:  J W van der Veen; R de Beer; P R Luyten; D van Ormondt
Journal:  Magn Reson Med       Date:  1988-01       Impact factor: 4.668

2.  Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs.

Authors:  D J Chaplin; B Acker; P L Olive
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-05       Impact factor: 7.038

3.  Tumor tissue oxygenation as evaluated by computerized-pO2-histography.

Authors:  F Kallinowski; R Zander; M Hoeckel; P Vaupel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-10       Impact factor: 7.038

4.  Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors.

Authors:  J Kalmus; P Okunieff; P Vaupel
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

5.  Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo.

Authors:  M R Horsman; K L Christensen; J Overgaard
Journal:  Int J Hyperthermia       Date:  1989 Mar-Apr       Impact factor: 3.914

6.  Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P-nuclear magnetic resonance spectroscopy.

Authors:  P Okunieff; F Kallinowski; P Vaupel; L J Neuringer
Journal:  J Natl Cancer Inst       Date:  1988-07-20       Impact factor: 13.506

7.  Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs.

Authors:  W D Voorhees; C F Babbs
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10

8.  Modification of the 31P magnetic resonance spectra of a rat tumour using vasodilators and its relationship to hypotension.

Authors:  G M Tozer; R J Maxwell; J R Griffiths; P Pham
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

9.  Bioreductive drugs and the selective induction of tumour hypoxia.

Authors:  J C Bremner; I J Stratford; J Bowler; G E Adams
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

10.  Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours.

Authors:  M R Horsman; M Nordsmark; M Høyer; J Overgaard
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

View more
  5 in total

Review 1.  Applications of magnetic resonance in model systems: cancer therapeutics.

Authors:  J L Evelhoch; R J Gillies; G S Karczmar; J A Koutcher; R J Maxwell; O Nalcioglu; N Raghunand; S M Ronen; B D Ross; H M Swartz
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).

Authors: 
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

3.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

Review 4.  Targeting the metabolic microenvironment of tumors.

Authors:  Kate M Bailey; Jonathan W Wojtkowiak; Arig Ibrahim Hashim; Robert J Gillies
Journal:  Adv Pharmacol       Date:  2012

5.  31P-magnetic resonance spectroscopy and 2H-magnetic resonance imaging studies of a panel of early-generation transplanted murine tumour models.

Authors:  S P Robinson; A van den Boogaart; R J Maxwell; J R Griffiths; E Hamilton; J C Waterton
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.